V. Summersby

Advances in lipid-lowering therapy through gene-silencing technologies

Latest Reviews

  • Review Article |

    Adult cardiac hypertrophy initially develops as an adaptive response to an increased workload, but this physiological growth can ultimately lead to pathological hypertrophy and disease. In this Review, Nakamura and Sadoshima summarize the characteristics and underlying mechanisms of physiological and pathological hypertrophy, and discuss possible therapeutic strategies targeting these pathways to prevent or reverse pathological hypertrophy.

    • Michinari Nakamura
    •  & Junichi Sadoshima
  • Review Article |

    This Review describes the relationship between urban and transport planning and the city environment, the main cardiovascular risk factors (including physical activity, hypertension, and obesity), and cardiovascular disease and mortality. Improved city planning that promotes physical activity, reduces levels of air pollution and noise, and increases green space could decrease the burden of cardiovascular disease.

    • Mark J. Nieuwenhuijsen
  • Review Article |

    In this Review, Katritsis and colleagues discuss the major factors underlying the clinical decision to perform revascularization in patients with stable coronary artery disease and examine the use and limitations of existing evidence on the choice for, and preferred methods of, revascularization, namely, CABG surgery versus percutaneous coronary intervention.

    • Demosthenes G. Katritsis
    • , Daniel B. Mark
    •  & Bernard J. Gersh
  • Review Article |

    In this Review, Serruys and colleagues describe the pathophysiology of unprotected left main coronary artery disease, discuss novel diagnostic approaches in light of new imaging techniques, and describe risk stratification models to help in the decision-making process for determining the best revascularization strategy in these patients.

    • Carlos Collet
    • , Davide Capodanno
    • , Yoshinobu Onuma
    • , Adrian Banning
    • , Gregg W. Stone
    • , David P. Taggart
    • , Joseph Sabik
    •  & Patrick W. Serruys
  • Review |

    Novel antisense oligonucleotide and small interfering RNA technology can be used to reduce levels of lipoproteins that cause cardiovascular disease. In this Review, Nordestgaard and colleagues describe the principles of these gene-silencing approaches and summarize the trials that have tested the efficacy of these approaches in patients at risk of cardiovascular disease.

    • Børge G. Nordestgaard
    • , Stephen J. Nicholls
    • , Anne Langsted
    • , Kausik K. Ray
    •  & Anne Tybjærg-Hansen
  • Review |

    Nitric oxide (NO) signalling has pleiotropic roles in biology and a crucial function in cardiovascular homeostasis. In this Review, Balligand and colleagues summarize the updated paradigms on NO synthase regulation, NO interaction with reactive oxidant species in specific subcellular compartments, and downstream effects of NO in target cardiovascular tissues under both physiological and pathological conditions.

    • Charlotte Farah
    • , Lauriane Y. M. Michel
    •  & Jean-Luc Balligand

News & Comment

Milestone

Anticoagulants

Chris Ryan/Macmillan Publishers Limited

Anticoagulants

Anticoagulant drugs are used to prevent and treat thrombotic disorders in millions of patients worldwide. This Milestone plots the history of anticoagulant drugs, starting with the discovery and clinical trials of heparin and warfarin.

Nature events Directory